Tuberculosis diagnostics market seen reaching $3.37 billion by 2030

The tuberculosis diagnostics market is projected to grow from $2.52 billion in 2026 to $3.37 billion by 2030, driven by rising TB cases, demand for faster testing and broader use of molecular diagnostics. Asia-Pacific held the largest market share in 2025 as health systems pushed harder for earlier detection and drug-resistance screening.

Why it matters: - Tuberculosis remains a major infectious disease threat, and faster diagnostics are central to earlier treatment and lower transmission. - Rising cases of TB, including drug-resistant infections, are pushing demand for tests that are more accurate, faster and easier to deploy. - The market outlook signals continued investment in molecular testing, point-of-care systems and AI-assisted tools.

What happened: - The Business Research Company projected the global tuberculosis diagnostics market will grow from $2.52 billion in 2026 to $3.37 billion by 2030. - The report said the market is expected to rise at a 7.5% compound annual growth rate from 2026 to 2030. - The company also estimated the market at $2.34 billion in 2025, increasing to $2.52 billion in 2026 at a 7.9% CAGR. - Asia-Pacific held the largest share of the global tuberculosis diagnostics market in 2025. - The report was published Sept. 1, 2026.

The details: - The market’s recent growth has been tied to the global TB burden, public health screening, smear microscopy infrastructure, international funding for TB control and use of culture-based diagnostics. - Future growth is expected to come from demand for rapid and precise TB detection, stronger identification of drug-resistant TB strains and expanded decentralized testing. - Investment in molecular diagnostics and integration of AI-assisted diagnostic tools are also expected to support growth. - The report highlighted wider use of molecular TB testing, rapid diagnostic platforms, improved drug-resistance detection, point-of-care testing and high-sensitivity technologies as key trends. - TB diagnostics are used to detect acid-fast bacilli in clinical samples, confirm infection and monitor treatment effectiveness. - The market analysis covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report included market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - A free sample and full report were available online: Download a free sample and View the full report.

Between the lines: - The forecast reflects a shift from legacy TB testing toward faster, more decentralized and more sensitive diagnostic methods. - Rising HIV/AIDS prevalence matters because weakened immune systems increase the risk of active TB infection, which can expand testing demand. - The report pointed to a 13.6% increase in TB cases in England in 2024 versus 2023, with notifications rising from 4,831 to 5,490, as one example of stronger demand.

What's next: - Demand is likely to keep rising as health systems expand screening and seek earlier detection of TB and drug-resistant strains. - The market’s next phase will likely be shaped by adoption of molecular testing, point-of-care platforms and AI-supported diagnostics. - Regional growth opportunities may remain strongest in Asia-Pacific, where the market already held the largest share.